The target brain binding site of levetiracetam (LEV) is synaptic vesicle glycoprotein 2A (SV2A). Up to now, only a homozygous pathogenic SV2A gene mutation was reported in human. We now report a novel heterozygous pathogenic SV2A gene mutation both in a girl and her mother result in epilepsy and poor response to LEV. Furthermore, the girl developed a new seizure type after using LEV. Our report had a clinical relevance that LEV could potentially produce contradictory efficacy in patients with SV2A gene mutation. If patients’ seizures became exacerbated while using LEV, SV2A gene testing is recommended.
CITATION STYLE
Wang, D., Zhou, Q., Ren, L., Lin, Y., Gao, L., Du, J., & Wang, Y. (2019). Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. Clinical Neurology and Neurosurgery, 181, 64–66. https://doi.org/10.1016/j.clineuro.2019.03.020
Mendeley helps you to discover research relevant for your work.